Company profilePharmaceutical#145 of 1,318 in Pakistan✓ No DRAP alerts

DYSON R L

Pharmaceutical company · 117 brands · 138 molecules

Ranked #7 of 178 companies in Antiinflammatory And Antirheumatic Products

117 registered products 28 pharmaceutical brands 138 distinct molecules 0 DRAP alerts

Company overview

117
registered products
28
pharmaceutical brands
138
distinct molecules
12
therapeutic classes
0
DRAP alerts

DYSON R L is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 117 product registrations across 138 distinct molecules. It is the 145th largest registrant in Pakistan by product count, and ranks 7th of 178 in Antiinflammatory And Antirheumatic Products. Its portfolio is concentrated in Antiinflammatory And Antirheumatic Products and Antivirals For Systemic Use. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by DYSON

64 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

43
ceilings with an approval date
0
not revised in 2+ years
2026
oldest approval year
202643

Top molecules by brand count

Metformin4 brands
Naproxen3 brands
Atorvastatin3 brands
Sitagliptin2 brands
Vildagliptin2 brands
Tramadol2 brands
Zinc2 brands
Esomeprazole2 brands
Piracetam2 brands

Therapeutic classes

Antiinflammatory And Antirheumatic Products · 13Antivirals For Systemic Use · 7Blood Glucose Lowering Drugs, Excluding Insulin · 6Antidepressants · 6Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 6Quinolone Antibacterials · 6Lipid Modifying Agents · 5Antihistamines For Systemic Use · 4Other Beta-Lactam, Cephalosporins & Penems · 4Antiepileptics · 4Gastro · 3Antiemetics & Antinauseants · 3

Conditions treated

Intestinal & Bowel Syndrome · 2Ulcer/Reflux/Flatulence/Acidity · 1Pain Killers · 1Oral Agents · 1Neuropathic Pain/Epilepsy/Convulsion · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official25 products · Rs 66.99 – Rs 51,593.3
DVAGO12 products · Rs 209 – Rs 590.2
Servaid10 products · Rs 205.94 – Rs 349.02
Median across source: Rs 352.45

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

GETZ PHARMA PAKISTAN (PVT) LTD. holds 240 molecules not in this portfolio
),Formoterol3 ) 20Mg} Folic AcidAcetazolamideAcyclovirAdrenalineAlbendazole
Horizon Pharmaceuticals (Pvt) Limited holds 113 molecules not in this portfolio
000 I.UAcyclovirAlbendazoleAmlodipineAmoxicillinAmoxycillin Base
GENOME PHARMACEUTICALS (PVT) LTD holds 86 molecules not in this portfolio
AcitretinAmlodipineAnastrazoleAnastrozoleAprepitantArtemether

Get the full profile for DYSON

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.